TrilliumBiO

Rockville, Maryland11–50 employeestrilliumbio.comLinkedIn

TrilliumBiO is a biomarker discovery and diagnostics company that develops and commercializes novel tests to translate scientific discoveries into clinical use. It partners with healthcare innovators to deliver customized, validated, physician-guided diagnostic solutions across complex medical needs.

Visit trilliumbio.com ↗

Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

TrilliumBiO’s visible milestones center on diagnostic commercialization and collaborations rather than disclosed financing. On July 29, 2025, the company announced a strategic collaboration with T-NeuroDx to commercialize blood-based biomarkers for Alzheimer’s disease. On December 9, 2025, it partnered with Swiss diagnostics company Oncobit to offer a uveal melanoma monitoring assay in the United States; the solution is identified as Oncular™. On May 26, 2026, TrilliumBiO was named Emerging Life Sciences Company of the Year at the Maryland Tech Council’s 2026 ICON Awards. In June 2026, the company launched LAMair™, a VEGF-D blood test for lymphangioleiomyomatosis, and announced a partnership with The LAM Foundation to support awareness, education, and diagnostic pathways. Together, these developments show activity across oncology, neurology, and rare pulmonary disease, with partners helping extend clinical use and disease-specific education. No funding amount or financing round is disclosed in the available company information.

Market position

TrilliumBiO operates at the intersection of biomarker discovery, clinical diagnostics, and test commercialization. Its stated offering spans assay development and validation as well as named testing programs, including AlphaID™ for alpha-1 antitrypsin deficiency, aPAP ClearPath™ for autoimmune pulmonary alveolar proteinosis, LAMair™ for lymphangioleiomyomatosis, and Oncular™ for uveal melanoma monitoring. The company also describes capabilities in next-generation sequencing, chemistry, immunology, molecular testing, AI algorithms, and tissue pathology, alongside EMR and EMR-Lite workflows. This combination differentiates its described model from a narrow single-assay focus: it can develop tests and support ordering and result delivery within clinical workflows. Oncobit and T-NeuroDx are named collaborators in specific diagnostic programs, not established competitors. Its market positioning is best characterized as a Rockville-based diagnostics developer and commercialization partner serving clinical, drug-development, and disease-specific testing needs.

Growth & opportunities

TrilliumBiO’s documented growth trajectory is marked by expanding diagnostic programs and partnerships, rather than a disclosed sequence of funding rounds or employee-growth figures. In July 2025, it announced work with T-NeuroDx on commercialization of blood-based Alzheimer’s disease biomarkers. In December 2025, its collaboration with Oncobit brought a uveal melanoma monitoring assay to the U.S. market, adding an oncology-focused offering. The June 2026 LAMair™ launch and partnership with The LAM Foundation extended the portfolio into rare pulmonary disease and paired test availability with awareness and education efforts. The company also received the Maryland Tech Council’s Emerging Life Sciences Company of the Year award in May 2026, a recognition of its activity in the regional life sciences sector. The company maintains a careers page and invites interested candidates to follow it for future opportunities; no specific open roles or hiring focus are identified. These milestones suggest portfolio and market-access expansion, while the pace and financial scale of growth remain unclear.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes TrilliumBiO distinct

reccy insights

What makes TrilliumBiO distinct

01Combines biomarker discovery with the development and commercialization of market-ready diagnostic tests.
02Offers customized, physician-guided solutions tailored to partner needs and clinical challenges.
03Provides capabilities across next-generation sequencing, chemistry, immunology, molecular testing, AI algorithms, and tissue pathology.
04Supports flexible EMR integration and EMR-Lite workflows for test ordering and secure result delivery.
05Operates in Rockville, Maryland, near the region’s life sciences resources.

Technology & products6

Technology & products

Biomarker Discovery and Diagnostic Development Services
Designs, validates, and scales biomarker-based diagnostic assays for clinical use, drug development, rare-disease research, and commercialization.
AlphaID™
A genetic screening and confirmatory testing program for alpha-1 antitrypsin deficiency using SERPINA1 genotyping, dried-blood-spot AAT quantification, and reflex variant analysis.
aPAP ClearPath™ Testing Program
A provider-ordered blood test program that measures GM-CSF autoantibodies to help confirm or rule out autoimmune pulmonary alveolar proteinosis.
LAMair™
A quantitative serum VEGF-D assay that supports evaluation, differential diagnosis, and longitudinal monitoring of suspected lymphangioleiomyomatosis.
Oncular™
A diagnostic monitoring solution for uveal melanoma developed with Oncobit to support assessment of disease status through laboratory-based biomarker analysis.
EMR Integration and EMR-Lite Workflows
Integrates diagnostic test ordering, requisition generation, specimen and result notifications, and secure result delivery into healthcare organizations’ existing workflows.

Show all 6 products

+ 3 more: LAMair™, Oncular™, EMR Integration and EMR-Lite Workflows

Recent updates5

Launches, partnerships and team changes from press coverage

Jun 29, 2026Product launch
TrilliumBiO launched LAMair, a VEGF-D blood test to support earlier identification and diagnosis of lymphangioleiomyomatosis, making it available to physicians and patients across the U.S.
prnewswire.com
Jun 29, 2026Partnership
TrilliumBiO and The LAM Foundation partnered to advance awareness, education, and diagnostic pathways for lymphangioleiomyomatosis (LAM), including joint educational initiatives and support for use of the LAMair VEGF-D test.
prnewswire.com
May 26, 2026Award
2026 ICON Awards – Emerging Life Sciences Company of the Year
Dec 9, 2025Product launch
TrilliumBiO and Swiss firm Oncobit introduced Oncobit’s uveal melanoma monitoring assay to the U.S. market through a collaboration.
genomeweb.com
Jul 29, 2025Partnership
TrilliumBiO and T-NeuroDx announced a strategic collaboration to commercialize blood-based biomarkers for Alzheimer’s disease and advance diagnostic solutions in neurology.
tradingview.com

Show all 5 updates

About TrilliumBiO

Products: Biomarker Discovery and Diagnostic Development Services, AlphaID™, aPAP ClearPath™ Testing Program, LAMair™, Oncular™, EMR Integration and EMR-Lite Workflows
Focus areas: Health Care, health diagnostics, medical, biomarker discovery, diagnostics, clinical laboratory, molecular diagnostics, NGS
Headquarters: Rockville, Maryland
Employees: 11–50